Search research articles
Contact Us
Filters
Showing results (421-430 of 455) with videos related to
Page
of 46
Sort By:
Gynecologic Oncology
|
January 15, 2019
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Michel Fabbro, Kathleen N Moore, Anne Dørum, et al.
International Journal of Surgery (London, England)
|
July 22, 2025
Surgical approach, preoperative LEEP/conization and patterns of recurrence and death in low-risk cervical cancer - exploratory analysis from the CCTG CX.5/SHAPE trial
Sven Mahner, Fabian Trillsch, Janice S Kwon, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 10, 2021
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis
Joanna Baum, Elena Ioana Braicu, Oliver Hunsicker, et al.
Oncology Research and Treatment
|
March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
Fabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.
JAMA Oncology
|
June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
Thomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.
Cancers
|
April 12, 2022
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Hanna Huebner, Lothar Häberle, Volkmar Müller, et al.
Gynecologic Oncology
|
March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
Ursula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 13, 2025
Experiences and expectations of advance directives in gynecological cancer patients (the NOGGO-expression X study)
Melisa Guelhan Inci, Ebru Ilter, Eva Roser, et al.
Bulletin Du Cancer
|
March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Philipp Harter, Gerhard Bogner, Luis Chiva, et al.
Page
of 46
Search research articles
Search
Showing results (421-430 of 455) with videos related to
Sort By:
Page
of 46
Gynecologic Oncology
|
January 15, 2019
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Michel Fabbro, Kathleen N Moore, Anne Dørum, et al.
International Journal of Surgery (London, England)
|
July 22, 2025
Surgical approach, preoperative LEEP/conization and patterns of recurrence and death in low-risk cervical cancer - exploratory analysis from the CCTG CX.5/SHAPE trial
Sven Mahner, Fabian Trillsch, Janice S Kwon, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
February 10, 2021
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis
Joanna Baum, Elena Ioana Braicu, Oliver Hunsicker, et al.
Oncology Research and Treatment
|
March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
Fabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.
JAMA Oncology
|
June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
Thomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.
Cancers
|
April 12, 2022
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Hanna Huebner, Lothar Häberle, Volkmar Müller, et al.
Gynecologic Oncology
|
March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
Ursula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 13, 2025
Experiences and expectations of advance directives in gynecological cancer patients (the NOGGO-expression X study)
Melisa Guelhan Inci, Ebru Ilter, Eva Roser, et al.
Bulletin Du Cancer
|
March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Philipp Harter, Gerhard Bogner, Luis Chiva, et al.
Page
of 46